How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?

被引：10

作者：

Bassetti, Matteo ^{[1
,2
]}

Peghin, Maddalena ^{[1
,2
]}

Carnelutti, Alessia ^{[1
,2
]}

Righi, Elda ^{[1
,2
]}

机构：

[1] Univ Udine, Dept Med, Infect Dis Clin, Udine, Italy

[2] Santa Maria Misericordia Hosp, Udine, Italy

来源：

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 38卷 / 03期

关键词：

hospital-acquired pneumonia; ventilator-acquired pneumonia; carbapenemase-producing Enterobacteriaceae; antibiotic therapy; multidrug-resistant gram negative; VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; RESPIRATORY-TRACT INFECTIONS; HOSPITAL-ACQUIRED PNEUMONIA; KLEBSIELLA-PNEUMONIAE; RISK-FACTORS; RESISTANT ENTEROBACTERIACEAE; COLISTIN METHANESULFONATE; RETROSPECTIVE ANALYSIS;

D O I：

10.1055/s-0037-1602656

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent a common problem in hospital setting worldwide. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are an emergent problem due to the lack of therapeutic options available, leading to significant increases in morbidity and mortality. CRE have frequently been reported both in HAP/VAP, but limited data regarding the optimal treatment strategy in this setting are available. This review focuses on the current epidemiology of CRE, with a specific focus on HAP/VAP. Moreover, we will suggest a possible strategy for the empiric and targeted treatment of HAP and VAP in which the involvement of CRE is suspected or is confirmed.

引用

页码：301 / 310

页数：10

共 72 条

[1] Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015 [J].

Albiger, B. ;

Glasner, C. ;

Struelens, M. J. ;

Grundmann, H. ;

Monnet, D. L. .

EUROSURVEILLANCE, 2015, 20 (45) :17-34

[2]

[Anonymous], EUCAST GUID DET RES

[3]

[Anonymous], 2011, RISK ASS SPREAD CARB, DOI DOI 10.2900/59034

[4] Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management [J].

Barbier, Francois ;

Andremont, Antoine ;

Wolff, Michel ;

Bouadma, Lila .

CURRENT OPINION IN PULMONARY MEDICINE, 2013, 19 (03) :216-228

[5] Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient [J].

Bassetti, Matteo ;

Luyt, Charles-Edouard ;

Nicolau, David P. ;

Pugin, Jerome .

ANNALS OF INTENSIVE CARE, 2016, 6

[6] New therapeutic options for respiratory tract infections [J].

Bassetti, Matteo ;

Righi, Elda ;

Carnelutti, Alessia .

CURRENT OPINION IN INFECTIOUS DISEASES, 2016, 29 (02) :178-186

[7] Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? [J].

Bassetti, Matteo ;

Welte, Tobias ;

Wunderink, Richard G. .

CRITICAL CARE, 2016, 20

[8] Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria [J].

Bassetti, Matteo ;

De Waele, Jan J. ;

Eggimann, Philippe ;

Garnacho-Montero, Jose ;

Kahlmeter, Gunnar ;

Menichetti, Francesco ;

Nicolau, David P. ;

Paiva, Jose Arturo ;

Tumbarello, Mario ;

Welte, Tobias ;

Wilcox, Mark ;

Zahar, Jean Ralph ;

Poulakou, Garyphallia .

INTENSIVE CARE MEDICINE, 2015, 41 (05) :776-795

[9]

Bassetti M, 2012, EXPERT REV ANTI-INFE, V10, P585, DOI [10.1586/eri.12.36, 10.1586/ERI.12.36]

[10] Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure [J].

Buehrle, Deanna J. ;

Shields, Ryan K. ;

Clarke, Lloyd G. ;

Potoski, Brian A. ;

Clancy, Cornelius J. ;

Nguyen, M. Hong .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)

← 1 2 3 4 5 6 7 8 →